GOODWILL, IPR&D AND OTHER INTANGIBLE ASSETS, NET (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Other intangible assets, net
Total IPR&D	$ 237,400,000		$ 237,400,000		$ 896,400,000
Finite-lived intangible assets
Other intangible assets, gross	1,454,427,000		1,454,427,000		791,427,000
Other intangible assets, net	1,322,382,000		1,322,382,000		721,066,000
Other intangible assets
Amortization expense	28,000,000	5,200,000	61,700,000	15,400,000
Estimated aggregate amortization of intangible assets
Remainder of 2014	28,002,000		28,002,000
2015	112,004,000		112,004,000
2016	110,724,000		110,724,000
2017	109,484,000		109,484,000
2018	109,484,000		109,484,000
2019 and thereafter	852,684,000		852,684,000
Total	1,322,382,000		1,322,382,000		721,066,000
Patents
Finite-lived intangible assets
Other intangible assets, gross	2,627,000		2,627,000		2,627,000
Less: accumulated amortization	(2,539,000)		(2,539,000)		(2,493,000)
Acquired technology rights
Finite-lived intangible assets
Other intangible assets, gross	1,451,800,000		1,451,800,000		788,800,000
Less: accumulated amortization	(129,506,000)		(129,506,000)		(67,868,000)
SIVEXTRO
Other intangible assets, net
Total IPR&D	0		0		659,000,000
SIVEXTRO | Acquired technology rights
Other intangible assets
Milestone payment capitalized	4,000,000		4,000,000
Bevenopran
Other intangible assets, net
Total IPR&D	43,400,000		43,400,000		43,400,000
ZERBAXA for HABP and VABP
Other intangible assets, net
Total IPR&D	174,000,000		174,000,000		174,000,000
ZERBAXA for cUTI and cIAI
Other intangible assets, net
Total IPR&D	$ 20,000,000		$ 20,000,000		$ 20,000,000